Online Webcast Teaches on Lymphoma. The survival rate of Hodgkin’s lymphoma has improved markedly over time and is now considered one of the most curable forms of cancer. Treatment for non-Hodgkin’s lymphoma has similarly seen great improvements rising from 31% five-year survival in the 1960s to now >75% five-year survival.
To review lymphoma and updates in treatment and outcomes, We’ve invited two of Ohio State University James Cancer Hospital’s Hematology experts. We’re pleased to introduce Assistant Professor of Hematology Dr Timothy Voorhees. Tim will be presenting today by pre-recorded video and will be focusing his talk on Diffuse Large B-cell Lymphoma. In the studio, we have Yazeed Sawalha who is an Assistant Professor of Hematology specializing in Hodgkin’s and B-cell non-Hodgkin’s lymphomas.
What you’ll learn in this webcast
- Methods to identify high-risk Diffuse Large B-cell Lymphoma.
- How to approach treatment for Diffuse Large B-cell Lymphoma.
- Discuss the common features of indolent B-cell lymphomas and how we approach them clinically.
- Briefly review treatment strategies for the 3 most common types of indolent B-cell lymphomas.
You’ll also learn about the following:
- Lymphoma Categories
- Lymphoma Workup
- Supporting Patients
You can find this and many other MedNet21 programs on the OSU – CCME website.
Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at firstname.lastname@example.org.